CN Patent

CN114920745B — 一种咪唑并吡嗪类化合物及其作为igf1r抑制剂的应用

Assigned to Chengdu Haibowei Pharmaceutical Co ltd · Expires 2024-05-24 · 2y expired

What this patent protects

本发明提供了一种咪唑并吡嗪类化合物，具有式I所示的结构或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式、药学上可接受的水合物、溶剂化物、盐或共晶。与现有技术相比，本发明提供的咪唑并吡嗪类化合物可作为IGF1R蛋白质激酶抑制剂，对IGF1R有较强的抑制活性，且具有良好的药代动力学性质，有很好的应用前景。

USPTO Abstract

本发明提供了一种咪唑并吡嗪类化合物，具有式I所示的结构或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体或其混合物形式、药学上可接受的水合物、溶剂化物、盐或共晶。与现有技术相比，本发明提供的咪唑并吡嗪类化合物可作为IGF1R蛋白质激酶抑制剂，对IGF1R有较强的抑制活性，且具有良好的药代动力学性质，有很好的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN114920745B
Jurisdiction
CN
Classification
—
Expires
2024-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Chengdu Haibowei Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.